Boric Acid Combined With Doxorubicin Demonstrates Antitumoral And Anti İnflammatory Effects in An Experimental Triple Negative Breast Cancer Model

Breast cancer is a disease where cells in the breast grow out of control, but not all cases are the same. One particularly aggressive form, known as triple-negative breast cancer, lacks specific receptors that doctors usually target with hormone therapies. Because these receptors are missing, treatment relies heavily on chemotherapy drugs that kill rapidly dividing cells. One of the most powerful tools in this fight is a drug called doxorubicin. It works by damaging the DNA inside cancer cells, preventing them from copying themselves and causing them to die. However, this drug is a double-edged sword. While it is effective against the tumor, it can also harm healthy organs, particularly the heart, and cause severe side effects that limit how much a patient can safely receive. Scientists have long searched for ways to make this drug work better while reducing the damage it causes to the rest of the body.

In a recent study, researchers explored a potential partner for doxorubicin: boric acid. While the name might sound like a household cleaner, boric acid is a naturally occurring substance found in many foods and even in the human body. It is known for having antioxidant and anti-inflammatory properties, meaning it can help calm the body's stress response and reduce swelling. The researchers wanted to see if adding this simple, natural compound to the standard chemotherapy treatment could boost the drug's ability to fight cancer while protecting the body from its harsh side effects. They focused on a specific type of triple-negative breast cancer that is known for spreading quickly to other organs, such as the lungs, liver, and kidneys.

To test this idea, the team first looked at cancer cells growing in a laboratory dish. They treated these cells with doxorubicin alone, boric acid alone, and a combination of both. They found that while doxorubicin alone slowed down the growth of the cells, adding boric acid made the drug significantly more effective at stopping the cells from multiplying and moving. The combination was particularly good at preventing the cells from spreading, a critical step in stopping cancer from moving to other parts of the body. The researchers calculated that the drug worked best at a very specific, tiny concentration, and when mixed with boric acid, the cells were much less likely to survive or migrate.

The study then moved to living animals to see how this combination would work in a complex, real-world system. The researchers used a group of mice that had been given a specific type of breast cancer tumor that naturally spreads to the lungs, liver, and bones, mimicking the way the disease behaves in humans. They divided the mice into four groups: one group received no treatment, a second received only the standard chemotherapy drug, a third received only boric acid, and the fourth received both together. Over the course of thirty days, the team monitored the size of the tumors and the overall health of the animals.

The results showed a clear difference between the groups. The mice that received the combination of doxorubicin and boric acid had the smallest tumors. Their bodies also held up better; while the group treated with chemotherapy alone lost some weight, a common sign of the drug's toxicity, the group receiving the combination maintained their weight more steadily. When the researchers examined the tissues after the experiment, they found that the combination treatment was the most effective at stopping the cancer from growing and spreading. In the tumors of the combination group, the markers for cell division were the lowest, while the signals for cell death were the highest. This means the cancer cells were dying off faster and not replacing themselves as quickly as in the other groups.

Beyond just shrinking the tumor, the combination treatment appeared to protect the other organs. The lungs, liver, and kidneys of the mice in the combination group looked much healthier than those in the other groups. The tissue structure in these organs remained organized and intact, with far less sign of inflammation or damage from the cancer. The researchers measured specific proteins that indicate inflammation and blood vessel growth, which tumors need to survive. In the combination group, these harmful signals were suppressed more effectively than in any other group. This suggests that boric acid may be helping to calm the body's inflammatory response, which often helps cancer grow and spread, while also making the chemotherapy drug more precise in its attack.

The study also looked at how the treatment affected the body's blood vessels. Tumors often create new blood vessels to feed themselves, a process driven by specific signals. The combination treatment significantly reduced these signals, effectively cutting off the tumor's food supply. At the same time, the treatment increased the activity of a protein that triggers cell suicide in the cancer cells. This dual action—starving the tumor while forcing it to self-destruct—was the strongest in the group receiving both substances. The researchers noted that this approach might help break a cycle where the stress of chemotherapy sometimes causes the body to release signals that help the cancer survive, but the addition of boric acid seemed to stop this counter-attack.

While the findings are promising, the researchers are careful to note that this was a preclinical study, meaning it was done in a controlled laboratory setting with mice, not in human patients. They also pointed out that they did not examine the heart tissue in this specific experiment, even though heart damage is a major concern with this type of chemotherapy. Future studies will need to confirm whether this protective effect extends to the heart and whether the results hold true in people. However, the study provides a strong reason to investigate boric acid further as a potential helper in cancer treatment. It suggests that a simple, naturally occurring substance could be used alongside standard drugs to make them work better and be safer, offering a new path forward for fighting one of the most difficult forms of breast cancer.